Metastatic Solid Tumor Clinical Trials in Columbus, Ohio

4 studies are recruiting for metastatic solid tumor in Columbus, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Ohio State University Hospital, Columbus, Ohio
    Locations
    33 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06561685 on ClinicalTrials.gov

  2. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of neladalkib (NVL-655), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evalu…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    OSU Brain & Spine Hospital, Columbus, Ohio
    Locations
    74 in total
    Run by
    Nuvalent Inc.

    See if you can join NCT05384626 on ClinicalTrials.gov

  3. A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

    Phase 1a/1b dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-330, determine the recommended Phase 2 dose (RP2D), and evaluate the antitumor activity in participants with advanced or metastatic human epidermal growth factor receptor 2 (HER2) -altered non-sm…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    OSU Brain and Spine Hospital, Columbus, Ohio
    Locations
    21 in total
    Run by
    Nuvalent Inc.

    See if you can join NCT06521554 on ClinicalTrials.gov

  4. A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

    Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid …

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Ohio State University, Columbus, Ohio
    Locations
    63 in total
    Run by
    Nuvalent Inc.

    See if you can join NCT05118789 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.